Dyadic International Inc. (NASDAQ:DYAI) Short Interest Up 25.7% in December

Dyadic International Inc. (NASDAQ:DYAI) was the recipient of a significant growth in short interest in the month of December. As of December 15th, there was short interest totaling 67,368 shares, a growth of 25.7% from the November 30th total of 53,615 shares. Based on an average daily trading volume, of 793,284 shares, the short-interest ratio is presently 0.1 days. Approximately 0.3% of the company’s shares are short sold. Approximately 0.3% of the company’s shares are short sold. Based on an average daily trading volume, of 793,284 shares, the short-interest ratio is presently 0.1 days.

Institutional Investors Weigh In On Dyadic International

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Marathon Capital Management purchased a new position in shares of Dyadic International during the 3rd quarter valued at approximately $41,000. Bank of America Corp DE increased its stake in shares of Dyadic International by 16,146.7% in the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after buying an additional 26,965 shares during the last quarter. AlphaCore Capital LLC acquired a new stake in Dyadic International in the second quarter valued at $50,000. Landscape Capital Management L.L.C. bought a new position in Dyadic International during the 3rd quarter valued at $190,000. Finally, Truist Financial Corp grew its holdings in Dyadic International by 30.5% during the 3rd quarter. Truist Financial Corp now owns 326,200 shares of the biotechnology company’s stock worth $385,000 after acquiring an additional 76,200 shares in the last quarter. 27.95% of the stock is currently owned by hedge funds and other institutional investors.

Dyadic International Stock Performance

Dyadic International stock opened at $0.94 on Friday. Dyadic International has a 12-month low of $0.71 and a 12-month high of $2.14. The company has a debt-to-equity ratio of 1.92, a current ratio of 2.85 and a quick ratio of 2.85. The company has a market capitalization of $34.02 million, a price-to-earnings ratio of -3.92 and a beta of 1.24. The firm’s fifty day moving average price is $0.97 and its 200 day moving average price is $0.99.

Dyadic International (NASDAQ:DYAI) last announced its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.02). Dyadic International had a negative net margin of 221.09% and a negative return on equity of 537.31%. The business had revenue of $1.16 million for the quarter, compared to analyst estimates of $1.22 million. On average, research analysts forecast that Dyadic International will post -0.18 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. HC Wainwright initiated coverage on shares of Dyadic International in a research report on Thursday, October 23rd. They issued a “buy” rating and a $3.00 price objective for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Dyadic International in a report on Monday. Finally, Craig Hallum started coverage on Dyadic International in a research report on Monday, September 8th. They issued a “buy” rating on the stock. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $3.00.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.